Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyxâs strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Source
No articles found.
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated t...
electroCore, Inc. is a commercial stage bioelec...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.